icotinamide and innate immunity in patients with bronchiectasis

Phase 1

• Conditions: Bronchiectasis; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12613000699763
• Lead Sponsor: Dr Conroy Wong, Middlemore Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Male or female aged between 18 to 80 years old
- able to provide written consent form
- Patients with confirmed bronchiectasis by High resolution
CT scan
- history of at least one pulmonary exacerbation in the
past 12 months
- healthy volunteers should be never smoker with no
underlying acute or chronic medical conditions and not
taking regular medications

Exclusion Criteria

- Pregnant or lactating women
- patients with significant medical conditions other than
bronchiectasis
- patients with significant abnormal liver function or with
liver cirrhosis
- patients with a history of non-adherence with medications

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dose of nicotinamide required to achieve serum level of 1 mM, this will be assessed by collecting blood samples for serum nicotinamide level analysis at each follow up visits from visit 2 to visit 5[two weeks]

Secondary Outcome Measures

Name	Time	Method
Counts of surviving bacterial colony-forming units after inoculation of the pathogen with nicotinamide treated blood[two weeks];Serum Level of C/EBPe expression [two weeks];serum lactoferrin level[two weeks];serum cathelicidin level[two weeks]